📊 ACRV Key Takeaways
Is Acrivon Therapeutics, Inc. (ACRV) a Good Investment?
Acrivon is a pre-revenue biotech company with severe cash burn, consuming $49.9M in free cash flow annually against only $35.4M in available cash, indicating critical runway constraints. The company exhibits clinical-stage pharmaceutical characteristics with no meaningful revenue generation, negative operating margins exceeding -64M, and deteriorating returns on both equity (-45.8%) and assets (-40.6%), making it fundamentally unprofitable.
Acrivon Therapeutics shows the classic profile of a pre-revenue biotech with no operating income, persistent losses, and deeply negative free cash flow. Its balance sheet is currently clean with strong liquidity and no long-term debt, but the annual cash burn relative to cash on hand suggests funding risk unless development milestones improve or additional capital is raised.
Why Buy Acrivon Therapeutics, Inc. Stock? ACRV Key Strengths
- Strong liquidity position with 8.75x current ratio providing near-term operational flexibility
- Solid balance sheet with equity of $128.6M and minimal debt obligations (0.0x debt-to-equity)
- Notable insider activity with 17 Form 4 filings suggesting active management engagement
- Strong near-term liquidity with 8.75x current and quick ratios
- Debt-free capital structure reduces financial leverage risk
- Equity base remains sizable at $128.60M versus only $16.70M of liabilities
ACRV Stock Risks: Acrivon Therapeutics, Inc. Investment Risks
- Critical cash burn rate of $49.9M annually against $35.4M cash reserves indicates less than 9 months of operations before insolvency without capital raises
- Complete absence of revenue with no clear path to profitability in near-to-medium term typical of pre-clinical stage therapeutics
- Persistent operating losses of -$64M and negative ROE/ROA of -45.8% and -40.6% respectively demonstrate fundamental unprofitability and value destruction
- No revenue base, leaving the business fully dependent on pipeline progress and external financing
- High annual operating and free cash flow burn relative to $35.41M cash balance
- Profitability remains weak with negative ROE of -45.8% and ROA of -40.6%
Key Metrics to Watch
- Quarterly cash burn rate and cash runway (critical for survival threshold)
- Clinical trial progression and regulatory milestone achievements for pipeline drugs
- Equity dilution from future capital raises and impact on share count and ownership
- Cash runway relative to operating cash burn
- Any emergence of collaboration revenue, milestone payments, or narrowing net loss
Acrivon Therapeutics, Inc. (ACRV) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 8.75x current ratio provides a solid financial cushion.
ACRV Profit Margin, ROE & Profitability Analysis
ACRV vs Healthcare Sector: How Acrivon Therapeutics, Inc. Compares
How Acrivon Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Acrivon Therapeutics, Inc. Stock Overvalued? ACRV Valuation Analysis 2026
Based on fundamental analysis, Acrivon Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Acrivon Therapeutics, Inc. Balance Sheet: ACRV Debt, Cash & Liquidity
ACRV Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Acrivon Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.38 indicates the company is currently unprofitable.
ACRV Revenue Growth, EPS Growth & YoY Performance
Acrivon Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
ACRV SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Acrivon Therapeutics, Inc. (CIK: 0001781174)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ACRV
What is the AI rating for ACRV?
Acrivon Therapeutics, Inc. (ACRV) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ACRV's key strengths?
Claude: Strong liquidity position with 8.75x current ratio providing near-term operational flexibility. Solid balance sheet with equity of $128.6M and minimal debt obligations (0.0x debt-to-equity). ChatGPT: Strong near-term liquidity with 8.75x current and quick ratios. Debt-free capital structure reduces financial leverage risk.
What are the risks of investing in ACRV?
Claude: Critical cash burn rate of $49.9M annually against $35.4M cash reserves indicates less than 9 months of operations before insolvency without capital raises. Complete absence of revenue with no clear path to profitability in near-to-medium term typical of pre-clinical stage therapeutics. ChatGPT: No revenue base, leaving the business fully dependent on pipeline progress and external financing. High annual operating and free cash flow burn relative to $35.41M cash balance.
What is ACRV's revenue and growth?
Acrivon Therapeutics, Inc. reported revenue of N/A.
Does ACRV pay dividends?
Acrivon Therapeutics, Inc. does not currently pay dividends.
Where can I find ACRV SEC filings?
Official SEC filings for Acrivon Therapeutics, Inc. (CIK: 0001781174) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ACRV's EPS?
Acrivon Therapeutics, Inc. has a diluted EPS of $-1.53.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ACRV a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Acrivon Therapeutics, Inc. has a SELL rating with 84% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ACRV stock overvalued or undervalued?
Valuation metrics for ACRV: ROE of -45.8% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ACRV stock in 2026?
Our dual AI analysis gives Acrivon Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ACRV's free cash flow?
Acrivon Therapeutics, Inc.'s operating cash flow is $-48.4M, with capital expenditures of $1.5M.
How does ACRV compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -45.8% (avg: 15%), current ratio 8.75 (avg: 2).